Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU -0.66%80 Return-on-Tangible-Asset is 2.64% as of Mar. 2026, which is 46% below its 10-year median of 4.92. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 80/100 and a GF Value™ of BDT315.25 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Orion Infusions ranks better than 55.36% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Orion Infusions's annualizedNet Income for the quarter that ended in Mar. 2026 was BDT22.1 Mil. Orion Infusions's average total tangible assets for the quarter that ended in Mar. 2026 was BDT838.2 Mil. Therefore, Orion Infusions's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 2.64%.
The historical rank and industry rank for Orion Infusions's Return-on-Tangible-Asset or its related term are showing as below:
DHA:ORIONINFU'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.06 Med: 4.92 Max: 15
Current: 4.2
During the past 13 years, Orion Infusions's highest Return-on-Tangible-Asset was 15.00%. The lowest was 4.06%. And the median was 4.92%.
DHA:ORIONINFU's Return-on-Tangible-Asset is ranked better than 55.36% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.12
vs DHA:ORIONINFU: 4.20
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Orion Infusions Return-on-Tangible-Asset Related Terms
Orion Infusions Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Orion Infusions's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Orion Infusions's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 2.64% mean?
Orion Infusions (DHA:ORIONINFU) has a Return-on-Tangible-Asset of 2.64% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orion Infusions and its competitors. This is 46% below median its historical median of 4.92. Over the past decade, Orion Infusions' Return-on-Tangible-Asset has ranged from 4.06 to 15.00. According to the industry distribution chart, Orion Infusions ranks #450 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Orion Infusions' Return-on-Tangible-Asset too high?
Orion Infusions' current Return-on-Tangible-Asset of 2.64% is 46% below median its 10-year median of 4.92. Over the past 10 years, this metric has ranged from a low of 4.06 to a high of 15.00. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.12. Orion Infusions' value of 2.64% is 15.4% below this industry median. Based on the distribution chart, Orion Infusions ranks #450 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orion Infusions has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #450 out of 1008 companies for Return-on-Tangible-Asset. This puts Orion Infusions in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.12. Orion Infusions' value of 2.64% is 15.4% below this benchmark. Historically, Orion Infusions' own Return-on-Tangible-Asset has ranged from 4.06 to 15.00 over the past decade. While the company's 10-year median is 4.92 vs. the industry median of 3.12, Orion Infusions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.12, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current Return-on-Tangible-Asset of 2.64% is 15.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current Return-on-Tangible-Asset is 2.64%, which is 46% below median its own 10-year median of 4.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT315.25, compared to a current price of BDT285.30 — trading 9.5% below its estimated fair value. The current Return-on-Tangible-Asset is 2.64%, which is 46% below median its 10-year median of 4.92 and 15.4% below the Drug Manufacturers industry median of 3.12. Orion Infusions' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Return-on-Tangible-Asset is 2.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT285.30 is trading 9.5% below its estimated GF Value™ of BDT315.25.
GuruFocus considers Orion Infusions to be Modestly Undervalued.
Key valuation signals for DHA:ORIONINFU:
Return-on-Tangible-Asset: 2.64% (46% below median its 10-year median of 4.92)
GF Value™: BDT315.25 vs. price of BDT285.30 (9.5% below fair value)
Industry Position: 15.4% below the Drug Manufacturers median (#450 of 1008)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
80GF Score
Get the complete analysis for DHA:ORIONINFU
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
